#Remepy
LightNews LightNews
techlensmedia.bsky.social
techlensmedia.com/news/remepy-...
Remepy Raises $36M to Advance Hybrid Drugs Into Phase III
Remepy raised $36M to advance Hybridopa into Phase III and expand its Hybrid Drug platform combining medicines with personalized AI-driven digital protocols.
techlensmedia.com
August 13, 2026 at 2:16 PM
newsen.bsky.social
Remepy Appoints Eran Harary, MD, to Propel Hybrid Drug Pipeline Forward#United_States#New_York#Remepy#Hybrid_Drugs#Eran_Harary
Remepy Appoints Eran Harary, MD, to Propel Hybrid Drug Pipeline Forward
Remepy has appointed Eran Harary, MD, as Chief Medical Officer to lead the advancement of its groundbreaking Hybrid Drug™ pipeline, particularly for Parkinson's disease.
third-news.com
September 16, 2026 at 11:39 AM
gav1nx.bsky.social
entrepreneurs-institute.com/a-parkinsons...
A Parkinson’s Drug Paired With Software Just Raised $36 Million to Prove It Works at Scale - Entrepreneurs Institute
Remepy, an Israeli biotech pioneering "Hybrid Drugs" that pair prescription medicines with AI-driven therapeutic software, has raised a $36 million Series A co-led by O.G. Venture Partners and M Ventu...
entrepreneurs-institute.com
August 18, 2026 at 6:04 PM
firstwordgroup.com
Remepy pockets $36M to push Parkinson's hybrid drug towards Phase III firstwordhealthtech.com/story/7843091
Loading...
firstwordhealthtech.com
August 13, 2026 at 1:04 AM
newsen.bsky.social
Remepy Secures $36 Million Series A to Enhance Hybrid Drug Development for Parkinson's Disease#USA#New_York#Remepy#Hybrid_Drugs#Hybridopa
Remepy Secures $36 Million Series A to Enhance Hybrid Drug Development for Parkinson's Disease
Remepy has successfully raised $36 million in a Series A funding round, boosting development for Hybridopa, aimed at Parkinson's disease treatment, and expanding its Hybrid Drug pipeline.
third-news.com
August 12, 2026 at 12:37 PM
l2plabs.bsky.social
Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease
Funding brings total capital raised to $62 million as the Company expands pharmaceutical co-development partnerships and accelerates the Hybrid Drug category NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Remepy, the pioneer of Hybrid Drugs, today announced the closing of a $36 million Series A...
dlvr.it
August 12, 2026 at 12:33 PM
pharmaphorum.bsky.social
#MerckKGaA has started working with #Remepy on the development of #hybriddrugs that combine a #medicine with #digitaltherapeutic (DTx) software to enhance its efficacy.

pharmaphorum.com/news/merck-p...
Merck partners Remepy in PDURS-focused alliance
Merck KGaA has started working with Remepy on the development of hybrid drugs that combine medicines with digital therapeutics.
pharmaphorum.com
April 29, 2026 at 8:07 AM
seeingwithsound.bsky.social
#Remepy's mobile app shown to rewire brain, modulate immune system and improve mood in adults with subjective cognitive decline www.prnewswire.com/news-release...
Remepy's Mobile App Shown to Rewire Brain, Modulate Immune System and Improve Mood in Adults with Subjective Cognitive Decline
/PRNewswire/ -- Remepy, a pioneer in hybrid drugs integrating digital and pharmacological interventions, announced today that RMPY-008, its multi-sensory...
www.prnewswire.com
July 1, 2025 at 5:35 PM
seeingwithsound.bsky.social
#Remepy: pioneering hybrid drugs www.remepy.com "applying principles of multi-sensory integration, sensory deprivation and sensory substitution"
Remepy
www.remepy.com
April 9, 2024 at 3:31 PM
newsen.bsky.social
New Mechanistic Evidence Enhancing Parkinson's Treatment with Hybridopa™ Revealed by Remepy#USA#New_York#Parkinson's#Hybridopa™#Hybrid_Drugs™
New Mechanistic Evidence Enhancing Parkinson's Treatment with Hybridopa™ Revealed by Remepy
Remepy's latest research reveals how its Hybrid Drug, Hybridopa™, improves Parkinson's patients' brain connectivity leading to better clinical outcomes. Discover the science!
third-news.com
July 1, 2026 at 11:16 AM
newsen.bsky.social
Remepy Achieves Positive Phase IIa Results for Hybridopa™, a Novel Treatment for Parkinson's Disease#USA#New_York#Parkinson's_Disease#Remepy#Hybridopa™
Remepy Achieves Positive Phase IIa Results for Hybridopa™, a Novel Treatment for Parkinson's Disease
Remepy announces promising Phase IIa trial outcomes for Hybridopa™, a ground-breaking therapy for Parkinson's disease, merging traditional medicine and digital protocols.
third-news.com
May 20, 2026 at 3:25 PM
newsen.bsky.social
Remepy and Merck KGaA Collaborate to Enhance Hybrid Drug Development Across Therapeutic Areas#USA#New_York#Remepy#Merk_KGaA#Hybrid_Drugs
Remepy and Merck KGaA Collaborate to Enhance Hybrid Drug Development Across Therapeutic Areas
Remepy announces a groundbreaking partnership with Merck KGaA to advance the research and development of Hybrid Drugs, merging pharmaceuticals with digital therapies.
third-news.com
April 28, 2026 at 11:16 AM
newsen.bsky.social
Remepy's Innovative App Enhances Brain Function and Mood in Adults with Cognitive Decline#USA#New_York#RMPY-008#Remepy#Cognitive_Decline
Remepy's Innovative App Enhances Brain Function and Mood in Adults with Cognitive Decline
Remepy's new app, RMPY-008, has demonstrated the ability to enhance brain connectivity, modulate the immune system, and improve mood in adults experiencing cognitive decline.
third-news.com
June 18, 2025 at 11:38 AM
jjfederer.bsky.social
Thoughts on a learning health care system and health data as a public good from the recent Remepy webinar.
January 23, 2025 at 7:38 PM
jjfederer.bsky.social
Thank you to the Remepy team for a great webinar about the PDURS guidance from @fda.gov The link for the full session is in the comments.
January 23, 2025 at 5:35 PM
l2plabs.bsky.social
Remepy Publishes New Evidence Showing its Hybrid Drug, Hybridopa™, Effect on Structural Connectivity in the Brain of Parkinson's Patients Associated with Improved Clinical Outcome
New npj Parkinson's Disease publication, building on the previously reported Hybridopa™ Phase IIa results, demonstrates for the first time, that behaviourally driven brain plasticity likely enhances the efficacy of dopaminergic treatment and provides both clinical and neurobiological...
dlvr.it
July 1, 2026 at 11:02 AM
l2plabs.bsky.social
Remepy Announces Collaboration with Merck KGaA, Darmstadt Germany to Advance Hybrid Drugs Across Therapeutic Areas
NEW YORK, April 28, 2026 /PRNewswire/ -- Remepy, the pioneer of Hybrid Drugs, today announced a collaboration with Merck KGaA, Darmstadt Germany, a leading science and technology company, to explore the development of Hybrid Drugs across multiple therapeutic areas. The collaboration will...
dlvr.it
April 28, 2026 at 11:05 AM
dominic-tyer.bsky.social
Merck KGaA and Remepy join forces to develop combo drug-digital therapies for rare cancers

www.pharmaceutical-technology.com/news/merck-k...

#pharma
Merck KGaA and Remepy join forces to develop combo drug-digital therapies - Pharmaceutical Technology
Merck KGaA and Remepy will work in tandem to develop drug-digital therapy combinations for a rare cancer indication.
www.pharmaceutical-technology.com
April 28, 2026 at 4:19 PM
firstwordgroup.com
Remepy, Merck KGaA pair up to test app-paired drug model in rare tumour firstwordpharma.com/story/7233714
April 29, 2026 at 12:45 AM